SERM
Sermorelin
The N-terminal 29 residues of human growth-hormone-releasing hormone, amidated at the C-terminus. This fragment is the shortest one that retains full activity at the GHRH receptor on the anterior pituitary; the remaining 15 residues of the natural hormone are not required for receptor binding.
No registered human study names Sermorelin as an intervention. ClinicalTrials.gov holds no trial of it, so there is no trial evidence to read — a fact about the public record rather than proof the compound does nothing. An FDA-approved product contains Sermorelin — GEREF (NDA019863). 17 papers naming it were published in the last ten years.
Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Counts include only trials whose registered intervention names Sermorelin; the registry search is fuzzy, so every match is re-checked. None of this says whether Sermorelin works or is safe.
FDA status
Approved
Human studies
0
Furthest phase
—
Papers, 10 yr
17
Readership
8,297
monthly average, Feb–Jul 2026
Tracking since 2026-07-29 · About this data
What has actually been tested in humans
Approved, but predates trial registration
0
Registered human studies
Approved
FDA-approved product — GEREF
27 loose registry matches were checked and 0 confirmed — 27 named something else and were discarded. We count a study only when Sermorelin is named as an intervention in it.
No study of Sermorelin in humans is registered on ClinicalTrials.gov. That is a fact about the public record, not a statement that the compound does nothing — but it does mean there is no trial evidence to read, and anyone telling you otherwise should be asked for the registration number. The grade is mechanical: it is computed from the registry and the FDA record alone, and it grades how much is known, never whether a compound is good or safe. Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Check the query.
What Sermorelin is, and what it has been studied for
Sermorelin is classified by ChEMBL as a protein. Its FDA substance identifier is 89243S03TE.
No registered trial names Sermorelin as an intervention, so there is no condition it has been formally studied in. It does have a literature: 17 indexed papers name it in the last ten years. That work is laboratory and animal research, and a paper is not a trial.
How far it got
Sermorelin has 0 registered trials, none of which records a phase.
An FDA-approved product contains Sermorelin. Approval covers a specific product for a specific use — it is not a verdict on the molecule.
Is anyone studying Sermorelin?
Papers published each year that name Sermorelin in the title or abstract, with the clinical trials that started in the same year marked beneath. Ten calendar years.
| Year | Publications | Trials started | Complete year |
|---|---|---|---|
| 2017 | 1 | 0 | Yes |
| 2018 | 0 | 0 | Yes |
| 2019 | 0 | 0 | Yes |
| 2020 | 2 | 0 | Yes |
| 2021 | 2 | 0 | Yes |
| 2022 | 2 | 0 | Yes |
| 2023 | 3 | 0 | Yes |
| 2024 | 1 | 0 | Yes |
| 2025 | 1 | 0 | Yes |
| 2026 | 6 | 0 | No |
17 papers between 2017 and 2026. A paper counts when “Sermorelin” appears in its title or abstract — phrase-matched, so a paper mentioning the words separately is not counted. The total is a single query over the whole window, which is why it does not equal the bars added together: PubMed files a paper under both its electronic and its print publication date, so one paper can appear in two years. Publication volume measures scientific attention, not whether a compound works: a well-studied compound can be well-studied and ineffective. Sources: PubMed and ClinicalTrials.gov · collected 2026-08-02.
Published research on Sermorelin
17 indexed papers name Sermorelin in their title or abstract. These are the 8 PubMed ranks most relevant. Listing a paper is not a judgement about it, and none of these is summarised here — follow the link and read what it says.
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions
- Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance
- Advances in the detection of growth hormone releasing hormone synthetic analogs
- Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?
- Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males
- Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency
- In-house standards derived from doping peptides: Enzymatic and serum stability and degradation profile of GHRP and GHRH-related peptides
- Cationic exchange SPE combined with triple quadrupole UHPLC-MS/MS for detection of GHRHs in urine samples
Collected 2026-08-02from PubMed, phrase-matched on “Sermorelin” in title and abstract. Run the same search.
About Sermorelin
The N-terminal 29 residues of human growth-hormone-releasing hormone, amidated at the C-terminus. This fragment is the shortest one that retains full activity at the GHRH receptor on the anterior pituitary; the remaining 15 residues of the natural hormone are not required for receptor binding.
- Also known as
- GRF 1-29
Structure and mechanism only. Nothing above describes what this compound is for, and no dose appears anywhere on this page.
Reading on this compound
All articles →PepRack articles that reference this compound. This is not a news feed — we syndicate nothing and publish no datelines.
Vendor listings are not affiliate links and PepRack earns nothing from them. A listing records a price we observed on a date. It is not a recommendation of a product, dose, or treatment, and PepRack does not verify what any vendor ships.